Ocular Therapeutix™ to Report First Quarter 2025 Financial Results on May 5, 2025
Ocular Therapeutix (NASDAQ: OCUL) announced it will release its first quarter 2025 financial results on Monday, May 5, 2025 at 7:00 AM Eastern Time. The biopharmaceutical company, focused on redefining the retina experience, stated it will not host a Q1 2025 conference call but plans to resume quarterly earnings calls starting with Q2 2025 results.
Ocular Therapeutix (NASDAQ: OCUL) ha annunciato che pubblicherà i risultati finanziari del primo trimestre 2025 lunedì 5 maggio 2025 alle 7:00 AM ora Eastern. L'azienda biofarmaceutica, specializzata nel ridefinire l'esperienza retinica, ha comunicato che non terrà una conference call per il primo trimestre 2025, ma prevede di riprendere le chiamate trimestrali sugli utili a partire dai risultati del secondo trimestre 2025.
Ocular Therapeutix (NASDAQ: OCUL) anunció que publicará sus resultados financieros del primer trimestre de 2025 el lunes 5 de mayo de 2025 a las 7:00 AM hora del Este. La compañía biofarmacéutica, enfocada en redefinir la experiencia de la retina, indicó que no realizará una llamada de conferencia para el primer trimestre de 2025, pero planea reanudar las llamadas trimestrales de resultados a partir del segundo trimestre de 2025.
Ocular Therapeutix(NASDAQ: OCUL)는 2025년 5월 5일 월요일 동부 시간 오전 7시에 2025년 1분기 재무 결과를 발표할 예정이라고 밝혔습니다. 망막 경험을 재정의하는 데 주력하는 이 생명공학 회사는 2025년 1분기 실적에 대한 컨퍼런스 콜은 진행하지 않으며, 2025년 2분기 실적부터 분기별 실적 발표 콜을 재개할 계획입니다.
Ocular Therapeutix (NASDAQ : OCUL) a annoncé qu'elle publiera ses résultats financiers du premier trimestre 2025 le lundi 5 mai 2025 à 7h00, heure de l'Est. Cette société biopharmaceutique, spécialisée dans la redéfinition de l'expérience rétinienne, a précisé qu'elle n'organisera pas de conférence téléphonique pour le premier trimestre 2025, mais prévoit de reprendre les appels trimestriels sur les résultats à partir du deuxième trimestre 2025.
Ocular Therapeutix (NASDAQ: OCUL) gab bekannt, dass die Finanzergebnisse für das erste Quartal 2025 am Montag, den 5. Mai 2025 um 7:00 Uhr Eastern Time veröffentlicht werden. Das biopharmazeutische Unternehmen, das sich auf die Neugestaltung der Retina-Erfahrung spezialisiert hat, erklärte, dass es für das erste Quartal 2025 keinen Telefonkonferenz geben wird, aber plant, die quartalsweisen Ergebnisgespräche ab dem zweiten Quartal 2025 wieder aufzunehmen.
- None.
- None.
BEDFORD, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced that it plans to issue a press release regarding first quarter 2025 financial results on Monday, May 5, 2025 at 7:00 AM Eastern Time. The Company will not be hosting a first quarter 2025 conference call and plans to resume quarterly earnings calls for its second quarter 2025 financial results.
Information about the Company’s quarterly results, conference calls, webcasts and other investor information are posted on the Company’s website.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (axitinib intravitreal hydrogel, also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD).
Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged 2 years or older, and in its investigational product candidate PAXTRAVA™ (travoprost intracameral injection or OTX-TIC), which is currently in a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension.
Follow the Company on its website, LinkedIn, or X.
The Ocular Therapeutix logo and DEXTENZA® are registered trademarks of Ocular Therapeutix, Inc. AXPAXLI™, PAXTRAVA™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.
Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
bslattery@ocutx.com
FAQ
When will Ocular Therapeutix (OCUL) release Q1 2025 earnings?
Will OCUL host a conference call for Q1 2025 earnings?
Where can investors find OCUL's quarterly financial information?
What is Ocular Therapeutix's main business focus?
